上周五，实盘买了一点$SIGA科技(SIGA)$ ，由于大盘盘中大跌，极度不稳，赚了一点就跑了，现在看来格局太小了！猴痘已经引起高层的关注，欧洲也计划接种猴痘疫苗，因此猴痘的行情很可能将持续一段时间！

猴痘是一种罕见的病毒性疾病，流行于尼日利亚、刚果民主共和国和中非共和国。尽管这种病毒不容易在人与人之间传播，但其死亡率在1%到15%之间，天花疫苗在预防猴痘方面可提供85%的有效性。

1972年天花根除后，全球大多数国家已经停止了常规的天花疫苗接种，在猴痘疫情爆发的情况下，青壮年可能将面临风险。

European Centre for Disease Prevention and Control Urges Eu Member States to Plan for Monkeypox Jabs
欧洲疾病预防和控制中心敦促欧盟成员国计划接种猴痘疫苗

Monkeypox is something 'everybody should be concerned about' and 'would be consequential,' if it spreads, says President Biden
美国总统拜登说，猴痘是每个人都应该关注的问题，如果它蔓延，将产生严重后果

Shares of Emergent BioSolutions Inc. (EBS) were up 11% last Friday. The biopharmaceutical company received a $2 billion contract from the U.S. Department of Health and Human Services in 2019 to supply its smallpox vaccine to the U.S., the Journal reported last week. Emergent's shares were up 9% in May but down 18.7% in the year to date.
Emergent BioSolutions Inc.的股价上周五上涨了11%。据《华尔街日报》上周报道，这家生物制药公司于2019年从美国卫生与公众服务部获得了一份价值20亿美元的合同，向美国供应天花疫苗。Emerent的股价在5月份上涨了9%，但今年迄今下跌了18.7%。

Meanwhile, SIGA Technologies Inc. (SIGA), a New York-based company, which said it received approval in Europe for its smallpox drug TPOXX, or tecovirimat, saw its shares soar 43% on Friday, bringing its stock up 65% so far in 2022.
与此同时，总部位于纽约的SIGA Technologies Inc.(SIGA Technologies Inc.)表示，其天花药物TPOXX(简称Tecovirimat)已在欧洲获得批准。上周五，SIGA Technologies Inc.的股价飙升了43%，2022年迄今已累计上涨65%。




$Emergent(EBS)$

$之江生物(SH688317)$